ES2113865T3 - Gen pnc humano y proteina precursora. - Google Patents

Gen pnc humano y proteina precursora.

Info

Publication number
ES2113865T3
ES2113865T3 ES91116557T ES91116557T ES2113865T3 ES 2113865 T3 ES2113865 T3 ES 2113865T3 ES 91116557 T ES91116557 T ES 91116557T ES 91116557 T ES91116557 T ES 91116557T ES 2113865 T3 ES2113865 T3 ES 2113865T3
Authority
ES
Spain
Prior art keywords
human
pnc
gen
precursor protein
cnp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91116557T
Other languages
English (en)
Inventor
Shoji Tanaka
Kayoko Fuchimura
Yasunori Tawaragi
Hisayuki Matsuo
Kenji Kangawa
Naoto Minamino
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Suntory Ltd
Original Assignee
Suntory Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suntory Ltd filed Critical Suntory Ltd
Application granted granted Critical
Publication of ES2113865T3 publication Critical patent/ES2113865T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

EL GEN DE UN CNP HUMANO (PEPTIDO NATRIURETICO DE TIPO C HUMANO), ASI COMO LA PROTEINA PRECURSORA DE HCNP QUE ESTA CODIFICADA POR ESTE GEN. EL PRECURSOR DE HCNP ESTA REPRESENTADO POR LA SIGUIENTE SECUENCIA DE AMINOACIDO. EL PRECURSOR DE HCNP Y SUS DERIVADOS SON NUEVOS Y TIENEN ACTIVIDADES NATRIURETICAS E HIPOTENSORAS.
ES91116557T 1990-09-27 1991-09-27 Gen pnc humano y proteina precursora. Expired - Lifetime ES2113865T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP02259698A JP3026354B2 (ja) 1990-09-27 1990-09-27 ヒトｃｎｐ遺伝子及び前駆体蛋白

Publications (1)

Publication Number Publication Date
ES2113865T3 true ES2113865T3 (es) 1998-05-16

Family

ID=17337688

Family Applications (2)

Application Number Title Priority Date Filing Date
ES96114549T Expired - Lifetime ES2302333T3 (es) 1990-09-27 1991-09-27 Gen de un cnp humano y proteina precursora.
ES91116557T Expired - Lifetime ES2113865T3 (es) 1990-09-27 1991-09-27 Gen pnc humano y proteina precursora.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES96114549T Expired - Lifetime ES2302333T3 (es) 1990-09-27 1991-09-27 Gen de un cnp humano y proteina precursora.

Country Status (8)

Country Link
US (1) US6034231A (es)
EP (2) EP0477971B1 (es)
JP (1) JP3026354B2 (es)
AT (2) ATE388165T1 (es)
DE (2) DE69133593T2 (es)
DK (1) DK0477971T3 (es)
ES (2) ES2302333T3 (es)
GR (1) GR3026554T3 (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL142118A0 (en) * 2001-03-20 2002-03-10 Prochon Biotech Ltd Method and composition for treatment of skeletal dysplasias
BRPI0203172B8 (pt) 2001-09-28 2021-05-25 Nakao Kazuwa composição farmacêutica para acondroplasia
DE60331584D1 (de) 2002-11-26 2010-04-15 Biocon Ltd Modifizierte natriuretic verbindungen, konjugate und ihre verwendungen
KR20070007842A (ko) * 2004-03-31 2007-01-16 카즈와 나카오 신장증가용 조성물
EP1759710B1 (en) 2004-03-31 2014-05-07 Kazuwa Nakao Remedy or preventive for arthritis
ES2365023T3 (es) 2004-04-21 2011-09-20 Enobia Pharma Inc. Conjugados de administración ósea y método de uso de los mismos para dirigir proteínas a hueso.
WO2006076471A2 (en) * 2005-01-12 2006-07-20 Nobex Corporation Bnp conjugates and methods of use
US20070184466A1 (en) * 2005-11-18 2007-08-09 The Brigham And Women's Hospital, Inc. Detection, generation and uses of atherosclerosis-protective endothelium
TWI367213B (en) * 2007-11-21 2012-07-01 Biomarin Pharm Inc Variants of c-type natriuretic peptide
PT2277890E (pt) * 2008-05-23 2016-03-31 Daiichi Sankyo Co Ltd Péptido capaz de prolongar o semi-período de vida do péptido de interesse no plasma
EP2432489B1 (en) 2009-05-20 2016-10-05 BioMarin Pharmaceutical Inc. Variants of c-type natriuretic peptide
US9266939B2 (en) 2010-12-27 2016-02-23 Alexion Pharmaceuticals, Inc. Compositions comprising natriuretic peptides and methods of use thereof
SG11201401605QA (en) 2011-10-19 2014-09-26 Alexion Pharma Holding Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
US10052366B2 (en) 2012-05-21 2018-08-21 Alexion Pharmaceuticsl, Inc. Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
US10822596B2 (en) 2014-07-11 2020-11-03 Alexion Pharmaceuticals, Inc. Compositions and methods for treating craniosynostosis
RU2708068C2 (ru) 2014-12-05 2019-12-04 Алексион Фармасьютикалз, Инк. Лечение судорог с использованием рекомбинантной щелочной фосфатазы
CA2973883A1 (en) 2015-01-28 2016-08-04 Alexion Pharmaceuticals, Inc. Methods of treating a subject with an alkaline phosphatase deficiency
MX2018001314A (es) 2015-07-30 2018-05-28 Biomarin Pharm Inc Uso de variantes de peptido natriuretico de tipo c para tratar displasia esqueletica.
US11352612B2 (en) 2015-08-17 2022-06-07 Alexion Pharmaceuticals, Inc. Manufacturing of alkaline phosphatases
EP3355904A4 (en) 2015-09-28 2019-06-12 Alexion Pharmaceuticals, Inc. IDENTIFICATION OF EFFECTIVE DOSE SHEETS FOR TISSUE-SPECIFIC ALKALINE PHOSPHATASE ENZYMERSAT THERAPY OF HYPOPHOSPHATASIA
EP3368062A4 (en) 2015-10-30 2019-07-03 Alexion Pharmaceuticals, Inc. METHODS OF TREATING CRANIOSYNOSTOSIS IN A PATIENT
SMT202600051T1 (it) 2016-01-08 2026-03-09 Ascendis Pharma Growth Disorders As Agonisti del cnp a rilascio controllato con effetti collaterali ridotti
US11065306B2 (en) 2016-03-08 2021-07-20 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in children
WO2017173395A1 (en) 2016-04-01 2017-10-05 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in adolescents and adults
WO2017173413A1 (en) 2016-04-01 2017-10-05 Alexion Pharmaceuticals, Inc. Treating muscle weakness with alkaline phosphatases
EP3464573B1 (en) 2016-06-06 2026-03-04 Alexion Pharmaceuticals, Inc. Metal impact on manufacturing of alkaline phosphatases
US11116821B2 (en) 2016-08-18 2021-09-14 Alexion Pharmaceuticals, Inc. Methods for treating tracheobronchomalacia
KR20240158374A (ko) 2017-03-31 2024-11-04 알렉시온 파마슈티칼스, 인코포레이티드 성인 및 청소년에서 저포스파타제증 (hpp)을 치료하는 방법
JP2021519590A (ja) 2018-03-30 2021-08-12 アレクシオン ファーマシューティカルズ， インコーポレイテッド 糖タンパク質の製造
JP7820148B2 (ja) 2018-08-10 2026-02-25 アレクシオン ファーマシューティカルズ， インコーポレイテッド アルカリホスファターゼを用いて神経線維腫症１型および関連状態を治療する方法
JP7758663B2 (ja) 2019-09-16 2025-10-22 バイオマリン ファーマシューティカル インコーポレイテッド Ｃｎｐバリアントおよびそのコンジュゲート
AU2020398898A1 (en) 2019-12-09 2022-07-21 Alexion Pharmaceuticals, Inc. Alkaline phosphatase polypeptides and methods of use thereof
US12083169B2 (en) 2021-02-12 2024-09-10 Alexion Pharmaceuticals, Inc. Alkaline phosphatase polypeptides and methods of use thereof
TW202313663A (zh) 2021-07-09 2023-04-01 美商拜奧馬林製藥公司 Ｃ型利鈉肽變異體治療兒童骨骼發育不良
IL313441A (en) 2021-12-07 2024-08-01 Biomarin Pharm Inc Cnp therapy
AU2023374630A1 (en) 2022-11-02 2025-05-01 Novo Nordisk A/S Cnp compounds
AU2024283779A1 (en) 2023-06-07 2026-01-22 Biomarin Pharmaceutical Inc. High throughput screen for genetic variants associated with short stature
WO2025101863A1 (en) 2023-11-08 2025-05-15 Biomarin Pharmaceutical Inc. Cnp variants, conjugates and formulations thereof
WO2026030743A1 (en) 2024-08-02 2026-02-05 Biomarin Pharmaceutical Inc. Treatment of short stature with cnp variants

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1339210C (en) * 1988-05-31 1997-08-05 John Lewicki Recombinant techniques for production of novel natriuretic and vasodilator peptides

Also Published As

Publication number Publication date
DK0477971T3 (da) 1998-09-21
DE69128754T2 (de) 1998-06-04
EP0477971A3 (en) 1992-09-09
EP0477971B1 (en) 1998-01-21
EP0769554B1 (en) 2008-03-05
DE69128754D1 (de) 1998-02-26
EP0769554A3 (en) 1997-05-28
JPH04139199A (ja) 1992-05-13
JP3026354B2 (ja) 2000-03-27
ATE162532T1 (de) 1998-02-15
EP0769554A2 (en) 1997-04-23
DE69133593T2 (de) 2009-04-02
DE69133593D1 (de) 2008-04-17
ATE388165T1 (de) 2008-03-15
EP0477971A2 (en) 1992-04-01
US6034231A (en) 2000-03-07
ES2302333T3 (es) 2008-07-01
GR3026554T3 (en) 1998-07-31

Similar Documents

Publication Publication Date Title
ES2113865T3 (es) Gen pnc humano y proteina precursora.
IL131016A0 (en) Selection of proteins using rna-protein fusions
ATE125269T1 (de) Radiomarkierte peptide mit antikoagulanswirkung.
ATE104348T1 (de) O-glycosyliertes ifn-alpha.
ES2184728T3 (es) Proteinas de union a la fibronectina.
ES548617A0 (es) Procedimiento para disociar peptidos y proteinas en el enla-ce metionilo
DE69010294D1 (de) Verwendung von Antiprogestomimetika zur Stimulierung des Eisprungs.
HU906270D0 (en) Anticoagulant peptides
ITRM920658A0 (it) Procedimento per la purificazione della proteina endotelina
ZA899247B (en) Anticoagulant peptides
DK0477217T3 (da) Stabiliserede, potente GRF-analoge
FI900075L (fi) Medvaexthormon bindande peptid.
ES2142840T3 (es) Proteina que se une al interferon alfa/beta, su preparacion y las composiciones farmaceuticas que la contienen.
FI944997L (fi) Parannettu rekombinantti-proteiinien tuotanto
NO177858C (no) Peptid
DE3869939D1 (de) Biologisch wirksame peptide.
DE59610098D1 (de) Protein mit anti-tumorwirkung
ITRM920517A1 (it) Procedimento di produzione della proteina sv-iv ricombinante e proteina sv-iv ricombinante.
ATE75255T1 (de) Peptid und dafuer kodierendes gen.
DK369888A (da) Peptidforbindelser
ATE103339T1 (de) Lymphokin-aehnliche peptide.
ATE95238T1 (de) Leader-anteile zur produktion von rekombinanten proteinen.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 477971

Country of ref document: ES